Core Viewpoint - Covalon Technologies Ltd. has granted a total of 97.674 Deferred Share Units (DSUs) to four non-employee directors as part of their annual directors' fees for fiscal year 2026, opting for DSUs instead of cash [1][2]. Group 1: Deferred Share Units (DSUs) - The DSUs were granted under the Amended and Restated Omnibus Long-Term Incentive Plan, effective March 25, 2026 [2]. - The DSUs will vest 12 months from the date of grant, with a deemed value calculated at $1.72 per share, based on the last closing price prior to the grant [2]. Group 2: Company Overview - Covalon is an advanced medical technologies company focused on improving patient outcomes through innovative medical products and technologies, including advanced wound care and surgical consumables [4]. - The company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF) [4].
Covalon Announces Grant of Deferred Share Units
Businesswire·2026-03-27 21:03